In Phase C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment right up until disorder progression or perhaps the members are not able to tolerate the study drugs. Celastrol was recognized as being a Myb inhibitor that suppressed https://clinical-trial-recruitmen79234.howeweb.com/32540481/top-latest-five-brd4-targeted-therapy-abbv-744-clinical-data-urban-news